Enveric Biosciences Relocates HQ to Cambridge, MA

Enveric Biosciences, a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, announced the relocation of its corporate headquarters to Cambridge, Massachusetts.

Enveric believes the move will foster stronger collaborations, facilitate recruitment, and enhance visibility within a vibrant life sciences cluster and a dynamic investor community.

This move will also advance the company’s EB-003 molecule. EB-003 is designed to deliver the therapeutic benefits of neuroplastogens while minimizing hallucinatory effects. 

Enveric recently unveiled that its lead development candidate, EB-003, is believed to be the first representative of a potential pharmacological class of neuroplastogens, defined by dual engagement of the 5-HT₂A and 5-HT₁B receptors.

With encouraging preclinical data supporting its differentiated profile, the company is advancing EB-003 toward an Investigational New Drug (IND) submission, with first-in-human studies anticipated in 2026.

“Relocating our headquarters to Cambridge represents an important step in Enveric’s growth trajectory,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “The Greater Boston biotech hub offers unparalleled access to scientific innovation, industry leadership, and capital markets. These advantages will be beneficial as we prepare to advance our lead molecule, EB-003, into first-in-human clinical trials and pursue our vision of transforming the treatment landscape for patients living with serious neuropsychiatric conditions.”